Innovent Buys Into Ascentage, Opening New China Biopharma Chapter

Combining Small, Large Molecule Expertise

 
• By Dexter Jie Yan

The unprecedented deal between two public Chinese biotechs, Innovent Biologics and Ascentage Pharma, potentially provides an opening for more such mega-million dollar deals to come.

Biotech Collaboration
The comprehensive collaboration between two Chinese biotechs charts a new route in the sector. • Source: Alamy

More from Deals

More from Business